A 23-year-old woman presented with a history of intellectual disability, ataxia and progressive decline of motor function after initial normal development. Neurological examination revealed microcephaly (head circumference is 50.5 cm; −3.6SD), horizontal nystagmus, evident dysmetria and a broad based gait with postural instability. Magnetic resonance imaging (MRI) of the brain at the age of 16 years showed mild cerebellar atrophy (not shown), which had progressed at the age of 23 (Fig. [1](#Fig1){ref-type="fig"}b and Fig. [1](#Fig1){ref-type="fig"}a shows control image for comparison). Several metabolic (e.g. congenital disorders of glycosylation type 1a) and genetic (e.g. Friedreich ataxia) disorders were excluded (see [Supplementary material](#Sec1){ref-type="sec"} for extended case description).Fig. 1Brain MRI showing cerebellar atrophy in our patient, compared to a control and a PCH2A patient. (**a**) T1-weighted midsagittal image of a control. (**b**) T1-weighted midsagittal image of our patient, aged 23. Enlarged extracerebellar liquor spaces indicate atrophy of cerebellar vermis. The pons is normal. (**c**) Midsaggital MPR-image of a PCH2A patient at 6 months of age shows severe flattening of the ventral pons and hypoplasia of the cerebellar vermis. (**d**) MPR coronal image of control. (**e**) MPR coronal image or our patient shows atrophy of cerebellar hemispheres. (**f**) MPR coronal image of PCH2A patient indicates severe cerebellar hypoplasia with relative sparing of the vermis, resulting in a typical dragonfly pattern

Whole exome sequencing (trio analysis) revealed a homozygous missense variant: c. 1321G \> A; p.(Gly441Arg) in exon 11 of the O-Phosphoseryl-tRNA selenocysteine tRNA synthase (*SEPSECS, NM_016955.3*) gene in the patient. Both parents were heterozygous carriers of this variant, that was predicted pathogenic by various in silico prediction programs (see [Supplementary material](#Sec1){ref-type="sec"}).

*SEPSECS* mutations are associated with pontocerebellar hypoplasia type 2D (PCH2D). PCH2 is a prenatal onset neurodegenerative disorder characterized by severe hypoplasia of cerebellum and pons (Fig. [1](#Fig1){ref-type="fig"}c). PCH2D is a very rare subtype of PCH2 characterized by profound intellectual disability, progressive microcephaly, spasticity, epilepsy and progressive cerebral and cerebellar atrophy (Agamy & Zeev [@CR1]). Additional features like axonal neuropathy, optic nerve atrophy, secondary mitochondrial dysfunction and early onset epileptic encephalopathy with burst suppression were later reported in patients with *SEPSECS* mutations (Anttonen et al [@CR2]; Pavlidou et al [@CR4]; Olson et al [@CR3]). Disease onset was early and psychomotor development was severely delayed or absent in these patients. Our findings indicate that *SEPSECS* mutations can also give rise to milder and later onset neurodegeneration. It is currently unknown why our patient's phenotype is so much milder. Possibly, the Gly441Arg missense mutation, which is located in the last exon of *SEPSECS*, results in a SEPSECS protein with a higher residual activity. This milder clinical presentation of *SEPSECS* mutations should be kept in mind in clinical care and when interpreting *SEPSECS* variants identified by whole exome sequencing.
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